CYP2C19 Genotype Predictor of Gastric Acid Suppression

Status Withdrawn

Clinical Trial Summary

If CYP2C19 genotype can predict the efficacy of healing erosive esophagitis and gastric acid secretion in patients taking once a day omeprazole.

Clinical Trial Description

Proton pump inhibitors are metabolized through the CYP2C19 hepatic enzyme system. Several variant genotypes of this enzyme exist which may lead to decreased, normal or increased metabolism of the proton pump inhibitor. With alteration of metabolism, the degree of gastric acid suppression achieved and efficacy in treating reflux could be affected. For example, Asian populations who have low activity of CYP2C19, commonly need lower doses of proton pump inhibitors to manage gastroesophageal reflux because of more sustained blood levels and availability of the drug. Theoretically, those patients who are rapid metabolizers would receive less effective treatment with proton pump inhibitors ;

Study Design

Related Conditions & MeSH terms

Esophagitis

Clinical Trial Details

NCT number	NCT01824199
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Withdrawn
Phase	Early Phase 1
Start date	March 2013
Completion date	November 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00284908` - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers	Phase 1
Completed	`NCT00272818` - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Recruiting	`NCT05326113` - The Effect of Physiotherapy on Post POEM Reflux	N/A
Recruiting	`NCT01696734` - Domperidone in Treating Patients With Gastrointestinal Disorders	Phase 3
Terminated	`NCT02575391` - The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer	Phase 1/Phase 2
Completed	`NCT00256529` - Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia	N/A
Completed	`NCT00123630` - A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab	Phase 2
Completed	`NCT00081315` - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT00471094` - Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis	Phase 2
Completed	`NCT00579410` - Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule	N/A
Recruiting	`NCT05109819` - Esophagus-sparing Radiotherapy for Metastatic Spinal Cord Compression.	N/A
Completed	`NCT01556919` - Esophageal Monitoring Device for Assessing Mucosal Impedance
Active, not recruiting	`NCT03835663` - The Bacterial Composition of the Stomach in Reflux Disease
Completed	`NCT00195208` - Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis	Phase 3
Completed	`NCT00175045` - Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis	Phase 2
Completed	`NCT05129670` - Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum	N/A
Recruiting	`NCT05004155` - Twenty Four Hour Ambulatory pH & Impedance Testing: Normative Data for Indian Population
Completed	`NCT03228147` - Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment	N/A
Completed	`NCT01322633` - Risk of Cancer Among Pantoprazole Users	N/A
Completed	`NCT00133770` - Intravenous (IV) Pantoprazole in Erosive Esophagitis	Phase 4